196 related articles for article (PubMed ID: 25901531)
1. Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.
Patel HJ; Patel PD; Ochiana SO; Yan P; Sun W; Patel MR; Shah SK; Tramentozzi E; Brooks J; Bolaender A; Shrestha L; Stephani R; Finotti P; Leifer C; Li Z; Gewirth DT; Taldone T; Chiosis G
J Med Chem; 2015 May; 58(9):3922-43. PubMed ID: 25901531
[TBL] [Abstract][Full Text] [Related]
2. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2.
Patel PD; Yan P; Seidler PM; Patel HJ; Sun W; Yang C; Que NS; Taldone T; Finotti P; Stephani RA; Gewirth DT; Chiosis G
Nat Chem Biol; 2013 Nov; 9(11):677-84. PubMed ID: 23995768
[TBL] [Abstract][Full Text] [Related]
3. NECA derivatives exploit the paralog-specific properties of the site 3 side pocket of Grp94, the endoplasmic reticulum Hsp90.
Huck JD; Que NLS; Immormino RM; Shrestha L; Taldone T; Chiosis G; Gewirth DT
J Biol Chem; 2019 Nov; 294(44):16010-16019. PubMed ID: 31501246
[TBL] [Abstract][Full Text] [Related]
4. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
[TBL] [Abstract][Full Text] [Related]
5. Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.
Mishra SJ; Ghosh S; Stothert AR; Dickey CA; Blagg BS
ACS Chem Biol; 2017 Jan; 12(1):244-253. PubMed ID: 27959508
[TBL] [Abstract][Full Text] [Related]
6. GRP94/gp96 in Cancer: Biology, Structure, Immunology, and Drug Development.
Wu BX; Hong F; Zhang Y; Ansa-Addo E; Li Z
Adv Cancer Res; 2016; 129():165-90. PubMed ID: 26916005
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
Llauger L; He H; Kim J; Aguirre J; Rosen N; Peters U; Davies P; Chiosis G
J Med Chem; 2005 Apr; 48(8):2892-905. PubMed ID: 15828828
[TBL] [Abstract][Full Text] [Related]
8. Development of Glucose Regulated Protein 94-Selective Inhibitors Based on the BnIm and Radamide Scaffold.
Crowley VM; Khandelwal A; Mishra S; Stothert AR; Huard DJ; Zhao J; Muth A; Duerfeldt AS; Kizziah JL; Lieberman RL; Dickey CA; Blagg BS
J Med Chem; 2016 Apr; 59(7):3471-88. PubMed ID: 27003516
[TBL] [Abstract][Full Text] [Related]
9. Unleashing the full potential of Hsp90 inhibitors as cancer therapeutics through simultaneous inactivation of Hsp90, Grp94, and TRAP1.
Park HK; Yoon NG; Lee JE; Hu S; Yoon S; Kim SY; Hong JH; Nam D; Chae YC; Park JB; Kang BH
Exp Mol Med; 2020 Jan; 52(1):79-91. PubMed ID: 31956271
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms.
Wright L; Barril X; Dymock B; Sheridan L; Surgenor A; Beswick M; Drysdale M; Collier A; Massey A; Davies N; Fink A; Fromont C; Aherne W; Boxall K; Sharp S; Workman P; Hubbard RE
Chem Biol; 2004 Jun; 11(6):775-85. PubMed ID: 15217611
[TBL] [Abstract][Full Text] [Related]
11. Trifunctional High-Throughput Screen Identifies Promising Scaffold To Inhibit Grp94 and Treat Myocilin-Associated Glaucoma.
Huard DJE; Crowley VM; Du Y; Cordova RA; Sun Z; Tomlin MO; Dickey CA; Koren J; Blair L; Fu H; Blagg BSJ; Lieberman RL
ACS Chem Biol; 2018 Apr; 13(4):933-941. PubMed ID: 29402077
[TBL] [Abstract][Full Text] [Related]
12. Purine-scaffold Hsp90 inhibitors.
Chiosis G; Tao H
IDrugs; 2006 Nov; 9(11):778-82. PubMed ID: 17096299
[TBL] [Abstract][Full Text] [Related]
13. Orally active purine-based inhibitors of the heat shock protein 90.
Biamonte MA; Shi J; Hong K; Hurst DC; Zhang L; Fan J; Busch DJ; Karjian PL; Maldonado AA; Sensintaffar JL; Yang YC; Kamal A; Lough RE; Lundgren K; Burrows FJ; Timony GA; Boehm MF; Kasibhatla SR
J Med Chem; 2006 Jan; 49(2):817-28. PubMed ID: 16420067
[TBL] [Abstract][Full Text] [Related]
14. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design.
Immormino RM; Metzger LE; Reardon PN; Dollins DE; Blagg BS; Gewirth DT
J Mol Biol; 2009 May; 388(5):1033-42. PubMed ID: 19361515
[TBL] [Abstract][Full Text] [Related]
15. Second Generation Grp94-Selective Inhibitors Provide Opportunities for the Inhibition of Metastatic Cancer.
Crowley VM; Huard DJE; Lieberman RL; Blagg BSJ
Chemistry; 2017 Nov; 23(62):15775-15782. PubMed ID: 28857290
[TBL] [Abstract][Full Text] [Related]
16. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase.
Chiosis G; Lucas B; Shtil A; Huezo H; Rosen N
Bioorg Med Chem; 2002 Nov; 10(11):3555-64. PubMed ID: 12213470
[TBL] [Abstract][Full Text] [Related]
17. Structural Basis for Design of New Purine-Based Inhibitors Targeting the Hydrophobic Binding Pocket of Hsp90.
Shin SC; El-Damasy AK; Lee JH; Seo SH; Kim JH; Seo YH; Lee Y; Yu JH; Bang EK; Kim EE; Keum G
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317068
[TBL] [Abstract][Full Text] [Related]
18. Dual Binding to Orthosteric and Allosteric Sites Enhances the Anticancer Activity of a TRAP1-Targeting Drug.
Hu S; Ferraro M; Thomas AP; Chung JM; Yoon NG; Seol JH; Kim S; Kim HU; An MY; Ok H; Jung HS; Ryu JH; Colombo G; Kang BH
J Med Chem; 2020 Mar; 63(6):2930-2940. PubMed ID: 32068404
[TBL] [Abstract][Full Text] [Related]
19. Ligand interactions in the adenosine nucleotide-binding domain of the Hsp90 chaperone, GRP94. I. Evidence for allosteric regulation of ligand binding.
Rosser MF; Nicchitta CV
J Biol Chem; 2000 Jul; 275(30):22798-805. PubMed ID: 10816561
[TBL] [Abstract][Full Text] [Related]
20. 5'-N-ethylcarboxamidoadenosine is not a paralog-specific Hsp90 inhibitor.
Liu S; Street TO
Protein Sci; 2016 Dec; 25(12):2209-2215. PubMed ID: 27667530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
